1-6 of 6
Matthew Ku, MBBS
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Mosunetuzumab Induces Complete Remissions in Poor Prognosis Non-Hodgkin Lymphoma Patients, Including Those Who Are Resistant to or Relapsing After Chimeric Antigen Receptor T-Cell (CAR-T) Therapies, and Is Active in Treatment through Multiple Lines

Stephen J Schuster, MD, Nancy L Bartlett, MD, Sarit Assouline, MD, Sung-Soo Yoon, MD PhD, Francesc Bosch, MD PhD, Laurie H Sehn, MD, Chan Y. Cheah, Mazyar Shadman, MD MPH, Gareth P Gregory, MBBS (Hons), PhD FRACP, FRCPA, Matthew Ku, MBBS, FRACP, FRCPA, PhD, Michael C Wei, MD PhD, Shen Yin, PhD, Antonia Kwan, MD PhD MRCPCH, Kasra Yousefi, MSc, Genevive Hernandez, PhD, Chi-Chung Li, PhD, Carol O'Hear, MD PhD, Lihua E Budde, MD PhD
Journal: Blood
Blood (2019) 134 (Supplement_1): 6.
https://doi.org/10.1182/blood-2019-123742
Published: 2019
Journal Articles

Characterization of Cardiovascular Adverse Events and B-Type Natriuretic Peptide Levels in Patients with Multiple Myeloma Who Are Treated with Carfilzomib

Hang Quach, MDFRACP,FRCPA,MBBS, Khue Minh Nguyen, Matthew Ku, MBBS, FRACP, FRCPA, Ali Bazargan, MBBS FRACP FRCPA, Robin J Filshie, PhDFRACP,FRCPA, Constantine S. Tam, MBBS, MD FRACP, FRCPA, Lisa Catherine Demosthenous, MPH, BSN, David Prior, MBBS FRACP PhD
Journal: Blood
Blood (2018) 132 (Supplement 1): 1956.
https://doi.org/10.1182/blood-2018-99-113802
Published: 2018
Journal Articles

Single Agent Oral Selinexor Demonstrates Deep and Durable Responses in Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL) in Both GCB and Non-GCB Subtypes: The Phase 2b Sadal Study

Marie Maerevoet, MD, Joost Vermaat, MD PhD, Miguel A. Canales, René-Olivier Casasnovas, MD, Eric Van Den Neste, Andre Goy, MD, Brian T. Hill, MD PhD, Catherine Thieblemont, MD PhD, Maria De Fatima De La Cruz, Federica Cavallo, MD PhD, George Follows, MD, Sylvain Choquet, MD, Ronit Gurion, MD, Reda Bouabdallah, MD, Ulrich Jaeger, MD, Agnes Nagy, MD, John Kuruvilla, MD, Krzysztof Warzocha, MD, Nagesh Kalakonda, MD, Paolo Caimi, MD, Sameer Bakhshi, MD, Matthew Ku, MBBS, FRACP, FRCPA, Nada Hamad, MD, Hendrik Veelken, MD PhD, Ewa Matczak, MD, Xiwen Ma, Jean-Richard Saint-Martin, Jatin J. Shah, MD, Michael G. Kauffman, MD PhD, Sharon Shacham, PhD MBA, Josée M Zijlstra, MD
Journal: Blood
Blood (2018) 132 (Supplement 1): 1677.
https://doi.org/10.1182/blood-2018-99-116868
Published: 2018
Journal Articles

High Major Response Rate, Including Very Good Partial Responses (VGPR), in Patients (pts) with Waldenstrom Macroglobulinemia (WM) Treated with the Highly Specific BTK Inhibitor Bgb-3111: Expansion Phase Results from an Ongoing Phase I Study

Constantine S. Tam, MBBS, Judith Trotman, MBChB, Stephen Opat, MD, Paula Marlton, MBBS, Gavin Cull, MBBS DM FRACP FRCPA, David Simpson, MBChB, FRACP, FRCPA, Matthew Ku, MBBS, David Ritchie, MD PhD, Emma Verner, FRACP, FRCPA, MBBS, Sumita Ratnasingam, MBBS, Mary Ann Anderson, MBBS, Peter Wood, MD FRACP, FRCPA, MBBS, Mark Kirschbaum, MD, Lai Wang, PhD, Ling Xue, Jianxin Yang, Eric Hedrick, John F Seymour, Andrew W. Roberts
Journal: Blood
Blood (2016) 128 (22): 1216.
https://doi.org/10.1182/blood.V128.22.1216.1216
Published: 2016
Journal Articles

Twice Daily Dosing with the Highly Specific BTK Inhibitor, Bgb-3111, Achieves Complete and Continuous BTK Occupancy in Lymph Nodes, and Is Associated with Durable Responses in Patients (pts) with Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)

Constantine S. Tam, MBBS, Stephen Opat, MD, Gavin Cull, MBBS DM FRACP FRCPA, Judith Trotman, MBChB, David Gottlieb, MBBS MD FRACP FRCPA, David Simpson, MBChB, FRACP, FRCPA, Paula Marlton, MBBS, Mary Ann Anderson, MBBS, Matthew Ku, MBBS, David Ritchie, MD PhD, Sumita Ratnasingam, MBBS, Bradley Augustson, Mark Kirschbaum, MD, Lai Wang, PhD, Ling Xue, Jianxin Yang, Eric Hedrick, John F Seymour, Andrew W. Roberts
Journal: Blood
Blood (2016) 128 (22): 642.
https://doi.org/10.1182/blood.V128.22.642.642
Published: 2016
Journal Articles

The BTK Inhibitor, Bgb-3111, Is Safe, Tolerable, and Highly Active in Patients with Relapsed/ Refractory B-Cell Malignancies: Initial Report of a Phase 1 First-in-Human Trial

Constantine Tam, MBBS, MD, Andrew P Grigg, MBBS MD, Stephen Opat, MBBS, Matthew Ku, MBBS, Michael Gilbertson, MBBS, Mary Ann Anderson, MBBS, John F. Seymour, MBBS, PhD, David S. Ritchie, MDPhD, Carmen Dicorleto, Belinda Dimovski, Eric Hedrick, Jianxin Yang, Lai Wang, PhD, Lusong Luo, Ling Xue, Andrew W. Roberts, MBBS, PhD
Journal: Blood
Blood (2015) 126 (23): 832.
https://doi.org/10.1182/blood.V126.23.832.832
Published: 2015